897934-60-0

Upstream product

• 5332-96-7 1-(4-nitrophenyl)propan-2-one 
• 20772-07-0 1-bromo-3-p-nitrophenylpropan-2-one 
• 17356-08-0 thiourea 

Downstream Products

• 91397-47-6 N-[4-(4-nitrobenzyl)-1,3-thiazol-2-yl]acetamide 
• 1426055-77-7 N-[4-(4-aminobenzyl)-1,3-thiazol-2-yl]acetamide 
• 1426121-88-1 N-[4-(4-carbamimidamidobenzyl)-1,3-thiazol-2-yl]acetamide 

Relevant academic research and scientific papers

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.

Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associ